Pharming Group announces updated full year 2023 guidance and expects 10% growth in Ruconest revenue, significantly exceeding prior guidance
Pharming Group announces updated full year 2023 guidance, including Ruconest revenues. For the full year 2023, total revenues are expected to increase by 19% to approximately US$245 million (preliminary and unaudited*).
Sijmen de Vries, Chief Executive Officer, commented: “We are pleased to have concluded an excellent year in which we transformed Pharming into a multi-product, commercial rare disease biopharmaceutical company. We expect 10% growth in Ruconest revenues, significantly exceeding our previous guidance for low single digit annual revenue growth.”
Updated 2023 guidance (preliminary and unaudited*) for Ruconest in HAE
- For the full year 2023, we expect Ruconest revenues to increase by 10% to approximately US$227 million, significantly exceeding our previous low single digit growth guidance.
- New patient enrollments in 2023 were up 25% vs. the prior year and were a significant driver of the strong Ruconest revenue growth achieved throughout 2023.
- In 2023, Pharming saw the first full-year, post-pandemic benefit of its first quarter 2020 restructuring and expansion of its U.S. salesforce. The Company achieved record numbers in leading metrics including increasing the Ruconest physician prescriber base by 13% during the year, in many cases adding previously unknown HAE prescribers.
* Updated guidance based on preliminary selected financial results that are unaudited and subject to adjustment. Pharming expects to issue full financial results for the fourth quarter and full year 2023 in March 2024. The Company has not completed its financial closing procedures for the quarter or year ended December 31, 2023 and actual results could differ from these preliminary financial results.
(Source: Pharming)
